The Orbera intragastric balloon (OIB) is a single fluid-filled intragastric balloon approved for the induction of weight loss and treatment of obesity. However, little is known about the effectiveness and safety of the OIB outside clinical trials, and since approval, the Food and Drug Administration has issued warnings to health care providers about risk of balloon hyperinflation requiring early removal, pancreatitis, and death. We analyzed data on patients who have received the OIB since its approval to determine its safety, effectiveness, and tolerance in real-world clinical settings.
O besity continues to be pervasive in our society, with more than two thirds of Americans being overweight or obese. 1 Although lifestyle interventions remain the cornerstone of therapy, because of a lack of long-term effectiveness, pharmacotherapies are becoming increasingly used as an adjunctive therapy. [2] [3] [4] Unfortunately, the proportion of patients that achieve greater than 10% of total body weight lost (TBWL) with lifestyle and pharmacologic therapies is limited. Achieving this magnitude of weight loss is needed to achieve resolution of more resistant comorbidities such as fatty liver and obstructive sleep apnea. 5 Bariatric surgery continues to be the most effective option for durable weight loss, but it carries its own set of risks and costs. 6, 7 Therefore, endoscopic bariatric therapies were developed to help bridge the gap between effectiveness and procedural risk to offer patients with obesity significant weight loss that allows them to better engage in a comprehensive lifelong weight maintenance program.
The Orbera intragastric balloon (OIB) (Apollo Endosurgery, Austin, TX) is 1 of 2 fluid-filled gastric balloons recently approved by the Food and Drug Administration (FDA) for patients with a body mass index (BMI) between 30 and 40 kg/m 2 . [8] [9] [10] Recent US multicenter randomized clinical trials showed the superiority of the OIB plus lifestyle interventions over lifestyle interventions alone, with patients losing 3 times more weight 6 months into balloon therapy. 11 However, the effectiveness and safety of the OIB outside clinical trials in the United States in a commercial setting is currently unknown, and, since approval, the FDA has issued 2 communications warning health care providers about the potential risks associated with fluid-filled intragastric balloons including the risk of balloon hyperinflation, pancreatitis, and death. 12, 13 Therefore, we sought to report the safety, effectiveness, and tolerance of the OIB across the United States in realworld clinical settings, including both academic and private practices involving surgeons and gastroenterologists and, finally, to derive predictors to optimize patient selection for this endoscopic bariatric therapy.
Methods

Study Design
This research study was an investigator-initiated, post-FDA regulatory approval, multicenter study using prospectively collected data. Since FDA approval of the OIB, the Mayo Clinic-Rochester created and hosted a comprehensive Research Electronic Data Capture database that records demographics, outcomes both in terms of weight loss and improvement in weight-related comorbidities, technical aspects of insertion and removal procedures, and detailed assessment of all potential adverse events associated with the device and or procedure. Eight US centers (3 academic, 5 private, 4 surgeons, and 4 gastroenterologists) participated. All centers received access to the Research Electronic Data Capture database and were prompted at regular intervals to enter data. Quality checks were conducted manually and centerspecific inquiries were obtained to ensure data integrity and completeness.
14 Participating institutional review boards approved the protocol and those without an institutional review board followed the principles outlined in the Declaration of Helsinki. Written informed consent was obtained from all subjects. All authors agreed to publish the manuscript and vouch for the completeness and accuracy of the data at their respective centers.
Intervention
Eligible patients included adults ages 18 to 65 years with a BMI greater than 30 kg/m 2 who received the OIB for the treatment of obesity in the United States after regulatory approval. All centers carefully followed the directions for use approved by the FDA in selecting patients. 8 All centers recommended following a reducedcalorie diet along with increased physical activity in conjunction with OIB therapy and had a minimum of 3 follow-up visits with a multidisciplinary team that included a nutritionist and/or a psychologist.
Study Outcomes
Primary effectiveness outcomes for the study were the percentage of TBWL (%TBWL) at 3, 6, and 9 months. The %TBWL was defined as weight lost at a specific time point (3, 6, or 9 mo) divided by the baseline weight at balloon placement. Secondary outcomes were absolute weight loss at 3, 6, and 9 months; the proportion of patients achieving at least 5% and 10% TBWL at 6 and 9 months; improvement in systolic and diastolic blood pressure total cholesterol, triglyceride, low-density lipoprotein, high-density lipoprotein, fasting blood sugar, and hemoglobin A1c levels; and resolution of hypertension, dyslipidemia, impaired fasting glucose, or type 2 diabetes at 6 months. Primary and secondary safety outcomes were rates of early balloon removal, periprocedural complications, dehydration episodes, balloon migration, balloon deflation or hyperinflation, pancreatitis, and other complications.
Statistical Analyses
Continuous variables were described by their means and SDs. Categoric variables were described by their frequencies. The %TBWL at 3, 6, and 9 months was compared with baseline weight using the paired t test with a 0.05 two-sided significance level. The paired t test additionally was used to compare baseline blood pressure and laboratory markers at 6 months. Exploratory multivariable linear and logistic regression analyses were performed to identify predictors of success and early balloon removal. All statistical analyses were conducted using JMP Pro version 13.0. (Cary, NC).
Results
Patient Characteristics
A total of 321 consecutive patients across 8 eight centers were included in the study. The mean age of the patients was 48.1 AE 11.9 years, 80% were female, and their mean baseline BMI was 37.9 AE 6.9 kg/m 2 ( Table 1) . At time of data analysis, 63% of the cohort had the OIB removed after completion of therapy and 37% still had the balloon in place.
Balloon Insertion
Of 321 patients, 99% (n ¼ 317) of the patients underwent balloon placement. Four patients did not receive the balloon because of pathology at endoscopy (n ¼ 1) and prior undisclosed gastrointestinal surgery (n ¼ 3). The average procedure insertion time was 8 AE 4.2 minutes. Further procedural details can be found in Table 2 . All patients were on a proton pump inhibitor for the duration of balloon therapy. All patients were started on at least 1 anti-emetic and antispasmodic medication for accommodative symptoms after OIB insertion, and only 86 (27%) patients received aprepitant (Emend Merck, Kenilworth, NJ) in addition to other antinausea medications prophylactically for nausea before placement. There were no serious intraprocedural complications reported, with only 1 balloon malfunction during placement that was followed by a successful immediate balloon replacement. Three patients (1%) were admitted for observation after the procedure.
After Balloon Insertion: 0 to 6 Months
After balloon placement, the mean total number of follow-up visits was 4.7 AE 3.7 during the first 6 months of therapy. Adverse events while the OIB was in place are summarized in Table 3 . Eight percent of patients (n ¼ 26) experienced dehydration resulting from vomiting, requiring a median of 1 intravenous infusion (range, 0-1 infusions) at an outpatient infusion center. Eight patients (3%) required a hospital admission to manage symptoms related to the OIB during balloon therapy, with 3 of those (1%) patients admitted for observation after OIB placement.
Early balloon removal rates were 16.6% (n ¼ 54), with a median time to removal of 8 weeks (range, 4.5-19.5 wk). Early removals were secondary to excessive symptoms in 75% of cases, and the remaining 25% were based on patients' request (work and travel schedule) with no troublesome symptoms. Symptoms necessitating early balloon removal included the following: vomiting (36%), nausea (21%), abdominal pain (8%), troublesome gastroesophageal reflux (8%), and a combination of the earlier-described symptoms (4%). One balloon spontaneously deflated but did not cause small-bowel obstruction or require surgical intervention. No balloon hyperinflations, pancreatitis, gastroesophageal perforations, or deaths were reported during the duration of the follow-up period. Table 4 summarizes predictors of OIB intolerance and early balloon removal (<8 wk). On univariable logistic regression, concurrent use of selective serotonin re-uptake inhibitor (SSRI) or serotonin-norepinephrine re-uptake inhibitor (SNRI) at the time of balloon placement, symptomatic gastroesophageal reflux disease at time of insertion, and diagnosis of depression were associated with increased odds of early removal. Only SSRI/SNRI use remained a significant predictor after adjusting for age and sex (odds ratio, 3.32; 95% CI, 1.01-10.88). Aprepitant use appeared to be protective 0.41 (range, 0.17-0.99; P ¼ .049) on univariable and multivariable analysis after adjusting for age and sex.
Predictors of Orbera Intragastric Balloon Intolerance and Early Removal
Balloon Removal
Balloon removal was uncomplicated in all patients, with 54% undergoing endotracheal intubation and the remainder performed under monitored anesthesia care. The balloon was successfully removed endoscopically in all patients without any need for surgical conversion. The mean time for removal was 12.5 AE 5.8 minutes. Food was found in the stomach at the time of removal in 28% of patients, with 1 reported case of aspiration under monitored anesthesia care after balloon removal that was managed with antibiotics. At balloon removal, 7% (n ¼ 12) of patients had esophagitis (grade A, 50%; grades B and C, 25% each). Small clean base ulcers were found in 1 patient, and 1 patient experienced a superficial esophageal tear managed with endoscopic clip placement as a prophylactic measure. Approximately 3% of patients (n ¼ 11) were admitted after removal for observation (Table 2) .
After Balloon Removal: 6 to 12 Months
The mean number of follow-up visits across all patients during the 3 months after balloon removal was 0.4 AE 1.25 visits. Only 6% (n ¼ 19) reported using antiobesity medications as a weight loss maintenance tool after balloon removal. Forty-seven (n ¼ 47) patients had follow-up visits at 9 months.
Weight Loss, Comorbidity Improvement, and Predictor of Weight Loss Data were available for 204, 199, and 47 patients at 3, 6, and 9 months after OIB insertion, respectively. The mean %TBWL at 3, 6, and 9 months was 8.5% AE 4.9%, 11.8% AE 7.5%, and 13.3% AE 9.5%, respectively. Patients continued to lose significant weight beyond 3 months with a %TBWL at 6 and 9 months that was significantly higher than that at 3 months (P < .01). The proportion of patients reaching 5%TBWL, 10%TBWL, and 15%TBWL at 6 months was 88%, 62%, and 31%, respectively (Supplementary Figure 1 and Table 5 ).
Subgroup analysis of OIB patients with obesityrelated comorbidities are summarized in Table 4 . Statistically significant changes in mean systolic blood pressure, total cholesterol, low-density lipoprotein, and triglycerides were seen. Hemoglobin A1C level was improved significantly by 0.7% at 6 months in prediabetic and diabetic patients (6.87 vs 6.1; P ¼ .006). Fortyone patients (45% of those with hypertension) were taken off their hypertension medication, and 25 patients (50% of those with type II diabetes) stopped or decreased their diabetes medication at 6 months. Table 6 summarizes the univariate and multivariable predictors of weight loss at 6 months after the OIB using a linear regression model. On multivariable analysis 
Discussion
This prospective post-US regulatory approval registry study of consecutive patients receiving a single fluidfilled intragastric balloon (OIB) in a variety of clinical practice settings showed similar efficacy at 6 months as that reported in the pivotal US randomized clinical trial, a more favorable safety profile, and durable weight loss 3 months after balloon removal. 11 Furthermore, we were able to show an impact on obesity-related comorbidities including hypertension, dyslipidemia, and diabetes.
Both the global burden of obesity study and a recent large individual-participant data meta-analyses of 239 prospective studies limited to never-smokers with no pre-existing disease showed that patients with mild-tomoderate obesity (BMI, 30-40 kg/m 2 ) are the highest contributors to the burden of disease in terms of both comorbidities mortality. 15, 16 This is secondary to a disproportionally higher percentage of patients in these obesity classes given the normal distribution of the disease, and the lack of effective weight loss interventions available. Standard lifestyle interventions typically only result in 3% to 5% TBWL, which is not durable over the long term and bariatric surgery is of limited appeal, cost, and risk profile to be a feasible or applicable strategy for this large cohort of patients with mild-to-moderate obesity. 17 The scientific literature is clear in showing that the magnitude of weight loss is highly relevant and strongly associated with improvements in obesity-related comorbidities and long-term weight maintenance. 18 The odds of clinically significant improvement in obesityrelated comorbidities are much higher when the % TBWL exceeds 10%. 5 Thus, both government agencies (the Agency for Healthcare Research and Quality) and national societies (the American Society of Bariatric and Metabolic Surgery and American Society for Gastrointestinal Endoscopy) now recognize that a significant management gap exists for patients with mild-tomoderate obesity. [19] [20] [21] In our study, the OIB resulted in more than 10% TBWL in the majority of patients, with improvement in obesity-related comorbidities. Furthermore, supplemented by a comprehensive multifaceted weight-maintenance program, the weight loss can persist after balloon removal. Given the demonstrated efficacy of OIB in producing significant weight loss and its excellent safety profile, it is a much-needed weight loss tool to bridge the management gap between medical and surgical obesity interventions. SNRI, serotonin-norepinephrine re-uptake inhibitor; SSRI, selective serotonin re-uptake inhibitor.
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a Adjusted for age, sex, baseline weight, and total weight loss at 3 months. b Removed because of collinearity with the SSRI/SNRI variable.
The paradigm for managing obesity has shifted to a model of chronic disease with an initial effective weightloss strategy followed by an aggressive weight-maintenance phase that counteracts the physiological and behavioral adaptations resulting from weight loss, using both obesity pharmacotherapies and behavioral interventions. In response to significant caloric restriction and loss of body fat stores, there are physiologic counter-regulatory processes that increase hunger, decrease satiety, and increase metabolic efficiency. 23 We previously have shown that the OIB modulates this compensatory hunger in response to caloric restriction by delaying gastric emptying, a fundamental physiologic regulator of appetite. [24] [25] [26] This delay in gastric emptying is reversed a few weeks after balloon removal; thus, it is intriguing to envision a strategy of sequential use of the OIB and antiobesity medications with synergistic mechanisms of action in patients who have responded favorably to OIB therapy. The Glucagon Like Peptide-1 (GLP-1) mimetic liraglutide (Saxenda; Novo Nordisk, Bagsvaerd, Denmark) is a potential synergistic candidate given its both central and peripheral mechanisms of action that delay gastric emptying and improve satiety. 27 Offering such a step-up, personalized-medicine approach that tailors the use of OIB and pharmacotherapies likely will minimize nonresponders and enhance the efficacy-to-risk ratio by providing an effective and durable nonsurgical weight loss option to this undertreated cohort with mild-tomoderate obesity.
This prospectively maintained clinical registry representing real-life US clinical practice has yielded multiple key observations about OIB tolerance, efficacy, and safety that were not obvious within the confines of the US pivotal clinical trial and from studies outside of the Unites States. These observations are of critical value to inform safe and effective use of the OIB in the United States. First, despite careful history, physical examination, and judicious screening before OIB use, 4 patients did not receive the balloon because of pathology found at the time of endoscopy including previously undisclosed gastroesophageal surgery, which is an absolute contraindication for use given the associated increased risk of perforation. Thus, careful endoscopic examination at the time of upper endoscopy, especially for evidence of previous surgery, peptic ulcer disease, large hiatal hernia, and undiagnosed eosinophilic esophagitis, is mandatory before OIB placement. Second, accommodative symptoms remain common after OIB placement. Although most of these symptoms resolved or improved within days after balloon placement, rates of early OIB removal because of intolerance remain high at 16.6% compared with 7.5% reported outside the United States, despite liberal use of medication to treat these symptoms and the self-pay nature of the procedure. 21 This argues that a certain percentage of patients will not tolerate OIB therapy. Identifying this cohort before balloon placement will be important. However, until better baseline clinical, psychological, and physiological predictors are defined, close patient follow-up evaluation and careful screening of those with a history of anxiety and depression for eligibility, ideally by a psychologist, is warranted. Of interest, SSRI/SNRI use was associated with balloon intolerance, a phenomenon that may be related to alterations in gastric emptying rates or related to underlying visceral hypersensitivity that predisposes patients to worse accommodative symptoms. The use of aprepitant (Emend) was only mildly beneficial in preventing early balloon removal owing to intolerance; thus, given its high cost, it is unlikely to be a cost-effective intervention in this cohort.
Equally important to predicting intolerance is predicting poor weight response. The hope for the future is to be able to stratify patients based on baseline gastric physiological measurement to precisely identify and offer those who are unlikely to respond alternative therapies. For now, early weight loss at 3 months was the strongest predictor of 6-month weight loss in addition to the number of follow-up visits with a multidisciplinary team. Thus, maximizing patient follow-up evaluation and intensifying therapy for those who achieve less than 7% TBWL at 3 months by the addition of anti-obesity medications and or enhanced early behavioral intervention is warranted. In the future, physiological predictors of intolerance and response likely will be identified to individualize patient care using office-based tools. 28 One such tool could be the recently FDA-approved 13C-Spirulina Gastric Emptying Breath Test (Cairn Diagnostics, Brentwood, TN). 29 Through medical device reporting, the FDA has issued 2 alerts to educate providers on the potential risks of acute pancreatitis, spontaneous balloon hyperinflation, and 5 reports of unanticipated deaths that occurred in patients with fluid-filled intragastric balloon systems to treat obesity. 12, 13 None of these complications were observed in our large cohort. Furthermore, the FDA was very careful to point out that they have not been able to definitely attribute the deaths to the balloons or the procedures to insert or remove the balloons. Previous publications have evaluated the incidence of death in patients treated with fluid-filled intragastric balloons. In 2015, the American Society for Gastrointestinal Endoscopy Bariatric Taskforce published a meta-analysis on the Orbera, which was the only intragastric balloon at the time with a sufficient number of publications to perform a meta-analysis. 21 Data were pooled from a manual review of adverse events from 68 studies. A total of 4 deaths occurred in this cohort, for a 0.08% incidence rate of death. Since receiving FDA approval in August 2015, the incident rate remains well below 0.01%. Compared with metabolic surgery, this rate is well below the risk of death associated with bariatric surgery, which ranges between 0.1% and 0.5%, depending on the surgical procedure. 22 The strength of this study includes its registry prospective design, allowing the investigation of real-world effectiveness across multiple centers, including private and academic centers, and involving gastroenterologists and surgeons. The limitations from this study include those inherent from a registry-based trial, including a significant loss to follow-up rate after balloon removal. Furthermore, not all centers had all data points collected such as impact on obesity comorbidity; thus allowing a more comprehensive analysis of OIB effects. However, a recent meta-analysis corroborated our findings and showed improvement in fasting blood sugar levels, cholesterol levels, and blood pressure results despite the low prevalence of comorbidities in those analyzed trials. 30 Although the OIB resulted in significant weight loss in our multicenter study, weight maintenance likely is a function of adherence to a healthy lifestyle and behaviors with adjunct obesity pharmacotherapies in selected patients. Despite efforts by all centers participating in this registry to provide patients with a comprehensive weight loss program, follow-up rates dropped after balloon removal. Although this is on par with most other weight loss interventions, it highlights the need for more intensive patient education, and setting realistic expectations and incentives for enhanced follow-up evaluation after balloon removal for better long-term outcomes.
Obesity is a chronic disease that warrants chronic management with lifelong lifestyle and pharmacotherapy similar to hypertension and type 2 diabetes. Endoscopic therapies such as intragastric balloons may offer a paradigm shift in our management of obesity that targets current gaps in therapy and should be viewed as an initial or step-up option for effective weight loss that gets patients better engaged with lifelong changes. Proportion of patients losing 5%, 10%, and 15% TBWL at 6 months.
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